

Technical Information

Bordet Gengou MiVeg Agar Base

Product Code: VM1175

Application:- Bordet Gengou MiVeg Agar Media is used for the detection and isolation of *Bordetella pertussis* and *Bordetella parapertussis*. Also used for the "cough plate" method in case of whooping cough.

Composition**

Ingredients	Gms / Litre
Potatoes infusion from	125.0
MiVeg peptone	10.00
Sodium chloride	5.50
Agar	20.00
Final pH (at 25°C)	6.7±0.2

^{**} Formula adjusted, standardized to suit performance parameters.

Principle & Interpretation

Bordet Gengou MiVeg Agar Base is prepared by using MiVeg peptones instead of peptic digest of animal tissue thus the media becomes BSE/TSE risk free. This medium is the modification of originally formulated media for cultivation of Bordetella species, by Bordet and Gengou (1). This media is used for diagnosing whooping cough from pharyngeal exudates, nasopharyngeal swabs. Cough plate technique are used for isolation of Bordetella pertussis - a causative agent of whooping cough. The medium contains Potato infusion and MiVeg peptone which serve as carbon and nitrogen source while glycerol and blood enrichment supplies additional nutrients required for the growth of organism. Being highly nutritious, these media support luxuriant growth of Bordetella and can be used for mass cultivation of Bordetella pertussis for vaccine production (2) and for maintaining stock cultures (1). Enrichment of the basal medium with 15% sheep blood aids in the detection of Bordetella pertussis by the virtue of its haemolytic reaction and with 25% human blood aids in the detection of Mycobacterium species from small sputum inocula and in Streptomycin sensitivity testing (3). Incubation should be carried out in a moist chamber (60% humidity) at 37°C for upto 7 days. Medium should not be overdried before use. After incubation Bordetella pertussis colonies appear smooth, raised, glistening with a zone of haemolysis. This media can be selective for Bordetella, by using antibiotics like Penicillin (4), Methicillin (5), Cephalexin (6) amongst which Cephalexin was found to be superior. Cephalexin is used at a concentration of 40 mg/litre. Amphotericin B (10 µg/ml) can be added as an antifungal agent to the medium.

Methodology

Suspend 40.0 grams of powder media in 1000 ml distilled water containing 10 ml Gycerol. Mix thoroughly. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Cool to 45-50°C and aseptically add 15 - 20% sterile, fresh defibrinated blood (sheep, rabbit, human or horse). Mix gently, taking care to avoid incorporation of air bubbles and pour into sterile petri plates.

Quality Control

Physical Appearance

Light yellow coloured, may have slightly greenish tinge, homogeneous, free flowing powder.

Gelling

Firm, comparable with 2.0% Agar gel.

Colour and Clarity of prepared medium

Basal medium yields, light yellow coloured clear to slightly opalescent gel, with addition of 15% v/v sterile defibrinated blood, cherry red coloured, opaque gel forms in petri plates.





Reaction

Reaction of 4.0 % w/v aqueous solution pH: 6.7±0.2 at 25°C

pH range

6.5-6.9

Cultural Response/Characteristics

Cultural characteristics observed after an incubation at 35 - 37°C for 3-4 days with added glycerol and 15% v/v sterile defibrinated blood.

Organisms (ATCC)	Growth	Haemolysis
Bordetella bronchiseptica (4617)	good - luxuriant	gamma
Bordetella pertussis (8467)	good - luxuriant	beta
Bordetella parapertussis (10521)	good - luxuriant	gamma

Storage and Shelf Life

Dried Media: Store below 30°C in tightly closed container and use before expiry date as mentioned on the label. **Prepared Media:** 2-80 in sealable plastic bags for 2-5 days.

Further Reading

- 1. Bordet J. and Gengou O., 1906, Ann. Inst. Pasteur, 20:731.
- 2. Kendrick P.L. and Eldering G., 1936, Am. J. Pub. Health, 26:506.
- 3. Tarshis M.S. and Frisch A.W., 1951, Am. J. Clin. Path., 21:101.
- 4. Flemming A., 1932, J. Path. Bact., 35:831.
- 5. Broome C.V., Fraser D.W. and English J.W., 1979, Internat. Symp. on Pertussis, DHEW, Washington, D.C., 19.
- 6. Suitcliffe E.M. and Abbott J.D., 1972, B.M.J., iii:732.

Disclaimer:

- User must ensure suitability of the product(s) in their application prior to use.
- The product conform solely to the technical information provided in this booklet and to the best of knowledge research and development work carried at CDH is true and accurate
- Central Drug House Pvt. Ltd. reserves the right to make changes to specifications and information related to the products at any time.
- Products are not intended for human or animal diagnostic or therapeutic use but for laboratory, research or further manufacturing of diagnostic reagents extra.
- Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for in
 fingement of any patents. Do not use the products if it fails to meet specifications for identity and performens parameters.

